Denosumab

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, according to a press release from Celltrion.

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a BMD T-score of at least –2.8 at the total hip or –3.1 at the lumbar spine at baseline, according to study findings.

The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced.

Among adults with osteoporosis on dialysis, use of denosumab significantly lowered fracture risk compared with bisphosphonate use, but cardiovascular risk was increased, according to study data.

Older women with chronic kidney disease who take denosumab may have a higher risk for emergently treated hypocalcemia compared with those treated with bisphosphonates, according to published data.

DESTIN, Fla. — Individualized treatment for osteoporosis calls for a keen understanding of the patient’s frame of mind, according to a speaker at the Congress of Clinical Rheumatology East.

NEW ORLEANS —Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting.

NEW ORLEANS —Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting.

Published results showed use of denosumab may reduce radiographic progression and prevent new erosive joints among patients with erosive hand osteoarthritis.

Adults with osteoporosis who received a full course of denosumab were less likely to develop incident diabetes than those who discontinued denosumab after the initial dose, according to study data published in JAMA Network Open.